Logo
Kura Oncology, Inc.

Executive Director, Clinical Development

Kura Oncology, Inc., Boston, Massachusetts, us, 02298


Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions. We're looking for a Senior/Executive Director, Clinical Development (MD) to lead cross-functional clinical teams for the design and conduct of clinical studies. This position will report to the EVP of Clinical Development.

ESSENTIAL JOB FUNCTIONS:

Lead cross-functional clinical teams for the design and conduct of oncology studies, specifically with the FTI franchise.

Ensure that scientific rigor and innovation drives Kura Oncology's development strategies.

Ensure excellence in both strategy and execution by partnering closely with colleagues in clinical operations, biostatistics, data management, program management and translational medicine.

Serve as Medical Monitor of sponsored clinical research and as medical representative to CROs, reference laboratories and other organizations involved in the execution of clinical trials.

Responsible for of all clinical regulatory deliverables and other clinical documents associated with the clinical trials under his/her direct responsibility, including protocols, and the clinical portion of INDs, CTAs, investigator brochures, CRF's, annual IND reports, CSR's and clinical expert reports, among others.

Responsible for the analysis of clinical data, including safety monitoring in collaboration with PV.

Participate in site initiation visits and other site visits at clinical center.

JOB SPECIFICATIONS:

Minimum of 3 years of relevant experience in drug development either in industry (preferred) or in academia. M.D. or Ph.D. degree required.

Proven track record of strong clinical research skills, including publications.

Ability to partner with others to implement innovative development strategies.

Experience in precision oncology/hematology preferred.

Demonstrated excellence in independently leading and conducting research and ability to evaluate, interpret and present complex scientific data.

Demonstrated written and excellent communication and interpersonal skills, with the ability to translate statistical concepts into layman's terms.

Strong attention to detail with ability to understand the broader picture and priorities.

Must be a dedicated self-starter with a high energy level and ability to achieve results.

Must have strong communication and leadership skills-the ability to influence and work successfully with colleagues, customers, and corporate partners.

The candidate should have experience in handling multiple projects at a time.

Some travel may be required when appropriate.

WORK ENVIRONMENT:

Employee frequently works in a professional office environment and lab with lots of computer/lab equipment, tools, and moderate amounts of noise and activity. Employee may occasionally be required to travel. The work environment is fast-paced and demanding. Off-shift, weekend and overtime duties may be required as assigned by the manager.

The base range for this role for a Senior Director is $320,000 to $378,000 and an Executive Director is $342,952 - $401,875 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura's Values that are used for candidate selection and performance assessments:

We work as one for patients

We are goal-focused and deliver with excellence

We are science-driven courageous innovators

We strive to bring out the best in each other and ourselves

The Kura Package

Career advancement/ development opportunities

Competitive comp package

Bonus

401K + Employer contributions

Generous stock options

ESPP Plan

20 days of PTO to start

18 Holidays (Including Summer & Winter Break)

Generous Benefits Package with a variety of plans available with a substantial employer match

Paid Paternity/Maternity Leave

In-Office Catered lunches

Home Office Setup

Lifestyle Spending Stipend

Commuter Stipend (Boston Office)

Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura's pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura's website atwww.kuraoncology.comand follow us onXandLinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.